Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Generic Makers Flock to Samsca’s Heart Failure Market after Patent Invalidated; Gx Listing Expected in December
A host of companies on August 15 obtained generic approval for a 15 mg OD tablet version of Otsuka Pharmaceutical’s diuretic agent Samsca (tolvaptan), which is indicated for use in heart failure patients, after a relevant patent was invalidated in…
To read the full story
Related Article
- Samsca Generics Extend Label to ADPKD
April 21, 2026
- First Generics for 5 APIs Join NHI Price List, Main Targets Are Nexium/Lexapro
December 9, 2022
- Samsca Generics Get Additional Indication for Heart Failure, AG Too
September 8, 2022
- First Generics for 5 APIs Approved towards December Listing, with 8 Firms for Nexium
August 16, 2022
REGULATORY
- AMED-Backed R&D Yielded 31 Regulatory Approvals in FY2025
July 17, 2026
- MHLW to Reconvene HSC Regulation Panel for First Time in a Year
July 17, 2026
- MHLW Allows Exceptional Concerta Pharmacy Transfers
July 17, 2026
- Japan to Consider Support for Domestic Immunoglobulin Production: Minister
July 16, 2026
- Govt Set to Amend Honebuto Draft over Inflation, MFN Language
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…